BRENTWOOD, Tenn. / Jul 22, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its second quarter 2025 results after the market closes on Tuesday, August 5, 2025. A conference call will be held the following day, Wednesday, August 6, 2025, at 10 a.m. ET to review the company’s financial results, discuss recent events and conduct a question-and-answer session.
A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent’s website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software.
To participate in the live teleconference:
United States Live: | 1-888-596-4144 |
International Live: | 1-646-968-2525 |
Access Code: | 4437657 |
To listen to a replay of the teleconference, which will be available through August 20, 2025:
United States Replay: | 1-800-770-2030 |
International Replay: | 1-609-800-9909 |
Access Code: | 4437657 |
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.
Last Trade: | US$12.76 |
Daily Change: | -0.26 -2.00 |
Daily Volume: | 279,431 |
Market Cap: | US$1.830B |
August 05, 2025 May 06, 2025 March 31, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load